Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
David Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, may have found a new home at the NYU Grossman School of Medicine.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
It can be difficult to prioritize getting organized, but taking precautionary steps can actually save you time in the long run. To help, here are nine organization strategies for busy professionals.
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Pheast, Apertura and Reify Health are BioSpace’s top financial winners this week. Read on to see what money can do!
All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.
Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.
Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
PRESS RELEASES
• ASCO 2026: 2.5-Year Overall Survival Data • Jefferies Healthcare Conference: Partnering & Investor meetings • BIO International Convention: Panel Participation • MIB Agents Factor Osteosarcoma Conference: Data Presentation
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
• MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. • Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
· Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG. · With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging